Why Biostate AI?

Today, pharma companies spend billions of dollars and multiple years to develop new drugs that benefit less than 20% of patients for each hyper-narrow disease. At Biostate, we want to create a single test that can guide clinical action across diseases. From one blood or tissue sample, we use RNA sequencing to capture the patient’s current biological state. Then our AI model interprets those signals and translates them into disease-specific clinical insights that can help identify early warning patterns that standard tests often miss. These insights enable doctors to make earlier, better-informed decisions and ultimately improve care for millions of patients worldwide.

Since its founding in 2023, Biostate has become a global constellation of organizations spanning 4 countries. We have established partnerships with dozens of leading hospitals including Harvard Medical School, MD Anderson Cancer Center, Cornell Weill Medical School, Peking Renmin Hospital (China), and Narayana Health (India) for multiple clinical research programs. Through these collaborations, we can obtain real-world clinical data to train our AI model, PRENN.

Biostate AI developed PRENN AI, our RNA foundation model for precision medicine. PRENN was pretrained on approximately 500,000 human RNA datasets, representing around 20 billion RNA tokens, combining public human RNA datasets with Biostate’s proprietary human RNA data. At this scale, PRENN can learn RNA patterns linked to disease activity, immune response, and treatment response.

We're redefining how we understand disease, shifting from late-stage diagnosis to early prediction. PRENN is designed to interpret RNA signals and support critical clinical decisions: Who is at high risk? Which condition does this patient most likely have? Which treatment is more likely to work? When should a patient avoid unnecessary procedures?

Our vision is not to build an AI model for a single disease, but a general foundation model that can support diagnosis, prognosis, and treatment decisions across many areas of human disease. Across cancer, autoimmune, infectious, metabolic, and rare disease programs, PRENN has shown promising results in many disease examples.

Our near-term clinical focus is autoimmune disease, beginning with multiple sclerosis, a complex autoimmune disease affecting more than 1 million Americans. Patients often experience vague symptoms and may wait 4–7 years for a definitive diagnosis, while irreversible neurological damage can continue to build.

Biostate has built the world’s largest molecular study of MS and NMO patients to date. As one application of PRENN, this study demonstrates how the same foundational model can be applied to a high-need autoimmune disease, using RNA signals to reveal clinically meaningful changes before conventional workflows can act.

From a single blood draw, we can now address three key clinical decisions that would normally take years of serial clinical followup:

1. Early Detection: Identify the high risk individuals before symptoms even appear or serious disability sets in, when treatment can still prevent and change the course of the disease.
2. MS vs. NMO: Distinguish between MS and NMO patients - two very similar diseases with overlapping symptoms and often similar imaging, where incorrect treatment can make outcomes worse.
3. Subtyping: Detect the subtle shift from relapsing to progressive disease earlier than doctors can see it, so the right therapy reaches the right patient before the window of action closes.

This is only one example of the broader opportunity we are building toward. We believe this is the beginning of a new era in precision medicine - one where AI can read the molecular state of the body and help doctors give the right treatment to the right patient at the right time.

Biostate's Series A (2025) was led by Accel (Series A investors in Facebook, Scale AI, Slack, and Discord), and Biostate's earliest investors include Dario Amodei (co-founder/CEO of Anthropic), Emily Leproust (co-founder/CEO of Twist Bioscience), and the California Institute of Technology.

These returns represent unrealized gains based on valuation increases from subsequent financing rounds. Previous investors have not yet received realized returns. Returns are not guaranteed.

From its 2023 Seed round, Biostate's investors have seen up to +210% gain on the value of their investments. These top investors believe and support Biostate's vision of a future of healthy living – will you join them?

The World Is Losing Billions of Healthy Years

Today, the average global life expectancy is about 71 years (WHO). Most people lose nearly two decades of healthy life not because their diseases were incurable, but because doctor prescribe treatment for the “average” patient instead of specifically optimized for them. Precision medicine has the power to change this, but it is currently accessible to less than 5% of the world.

If we can extend healthy lifespan to 90, the impact will be enormous: adding 19 extra healthy years to each of Earth’s 8 billion people creates a combined 150 billion healthy years of life.

According to the ICER, each Quality-Adjusted Life Year (QALY) is worth $100,000–$150,000. That means we will generate over $3,000 trillion of global value, 25× the current annual world GDP.

This is why our mission matters.

Biostate has been working on the innovation of multiomics testing and advanced AI technologies to achieve this mission, and allowing your grandparents, your parents, and you to live longer and happier without battling the specter of disease.

DNA and RNA sequencing technologies used today were invented in a different era and not intended to scale to millions of people. Genetic tests like Foundation One for cancer have a price tag of over $3000 to analyze 500 genes. We've invented and deployed technology to do genetic analysis for less than $50, and on 30,000 genes rather than 500. This uniquely allows us to scale data collection to millions of patient samples, with proper informed consent and physician support, in order to train powerful medical AI.

1. 10× lower cost than traditional RNA sequencing
2. 10× less input required: one FFPE curl or 1 mL of plasma can uncover 30,000+ genes
3. Works on damaged, degraded, or ultra-small samples that normally fail in standard pipelines

1. 8x lower cost than traditional DNA sequencing (Higher margin)
2. >95% uniform coverage at 30× depth, high diagnostic reliability
3. 260% improvement in notoriously difficult GC-rich regions

Modern general-purpose AI models were not built to analyze terabytes of human molecular data. DNA or RNA sequencing data from a single person is usually 5000x larger than ChatGPT's working memory(100,000 words). That’s why we built K-Dense - an autonomous AI scientist specializing in bio/medicine and outperforming ChatGPT, Gemini, and Deepseek by 60%.

Working with Dr. David Sinclair, one of the world’s leading aging researchers, K-Dense helped build one of the most accurate models for predicting biological age. In the process, K-Dense discovered four new RNA biomarkers of aging, uncovering biology that had never been documented before.

Go to Market

Our pricing is simple.

RNA tests cost $80 per sample. DNA tests cost $125 per sample. Gross margins are above 70%.

In the U.S. alone, cancer diagnostic testing represents a market of over $70B, with more than $25B per year coming from repeat tests, and this market continues to grow each year.

This is only part of a larger opportunity across many additional disease areas where Biostate’s technology can create substantial value.

With operations across the United States, China, India, and the Middle East, Biostate operates inside the world’s fastest-growing healthcare markets:

1. China: 1.4B population; rapidly developing pharmaceutical industry building new drugs
2. India: 1.4B population; world's greatest manufacturer of affordable generic and biosimilar drugs
3. Saudi Arabia: Spiritual center of the 1.8B Muslim world with over 100 million worldwide pilgrims per year; strong government initiatives and incentives to modernize health through Vision 2030.

No other precision-medicine company combines global wet labs, AI platforms, and multiomic pipelines across these regions exactly like us.

Our leadership team combines deep scientific expertise, proven company-building experience, and global operational leadership. Led by a repeat founder with a strong track record in molecular diagnostics and supported by seasoned financial and technical executives, the team brings together strengths across biotech, AI, and international markets—positioning Biostate.ai to execute at scale and translate cutting-edge science into real-world impact.

This advisory board brings together world-class clinicians, researchers, and innovators from leading institutions to guide and support Biostate.ai’s mission.

Backed by expertise across genomics, cancer, cardiovascular, autoimmune, and rare diseases, these advisors provide critical scientific, clinical, and strategic insight—ensuring our technology is credible, clinically relevant, and built to scale real-world impact.

Multi-Engine Revenue Growth

Biostate AI is scaling through multiple high-margin growth engines: U.S. clinical diagnostics, proprietary AI software (K-Dense), and expansion across India, China, and the Middle East.

Forward-looking projections are not guaranteed. The $10.5M projection includes both organic growth and strategic expansion. Organically, we project ~$1.5M in 2026 for Biostate, and ~$3M on a consolidated basis including subsidiaries and spinouts. The higher projection reflects our strategy to expand sequencing capacity and selectively acquire profitable sequencing labs.

Revenue is projected to grow from $10.5M in 2026 to $180M by 2029, driven by repeat testing, AI licensing, and global market access. With gross margins above 70%, this growth supports strong operating leverage and long-term enterprise value.

Join us in creating a future where precision medicine works for everyone.